Accueil/Actions/KTTA

KTTA

USD

Pasithea Therapeutics Corp. Common Stock

$0.690+0.010 (1.471%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.680

Haut

$0.710

Bas

$0.650

Volume

0.08M

Fondamentaux de l'Entreprise

Capitalisation Boursière

5.1M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.13M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.65Actuel $0.690Haut $3.85

Actualités Connexes

4 nov. 2025 · 12:03

GlobeNewswire

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Actions Connexes

NPWR

NET Power Inc.

NASDAQ

Industrial Mach...

FULTP

Fulton Financial Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A

NASDAQ

Grandes banques